2021 EASL意见书：慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗

2021-02-06 欧洲肝脏研究学会 J Hepatol . 2021 Feb 6;

2021年2月，欧洲肝脏研究学会(EASL)发布了慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗的意见书。本文主要总结了疫苗的安全性、免疫源性以及在上述患者群体中的疗效数据，并针对这些患者接种

中文标题：

英文标题：

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

发布机构：

欧洲肝脏研究学会

发布日期：

2021-02-06

简要介绍：

2021年2月，欧洲肝脏研究学会(EASL)发布了慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗的意见书。本文主要总结了疫苗的安全性、免疫源性以及在上述患者群体中的疗效数据，并针对这些患者接种COVID-19疫苗提供指导。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=a37321c00206ea1f, title=2021 EASL意见书：慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗, enTitle=EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients, guiderFrom=J Hepatol . 2021 Feb 6;, authorId=0, author=, summary=2021年2月，欧洲肝脏研究学会(EASL)发布了慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗的意见书。本文主要总结了疫苗的安全性、免疫源性以及在上述患者群体中的疗效数据，并针对这些患者接种, cover=https://img.medsci.cn/202138/1615138489777_2020535.jpg, journalId=0, articlesId=null, associationId=84, associationName=欧洲肝脏研究学会, associationIntro=欧洲肝脏研究学会（European Association for the Study of the Liver,EASL），是目前在欧洲居于首要地位的肝病学会，其发布的指南包括各种肝病的处理，同时对诊断、治疗和预防方法进行规范化定义。该协会下属的指南组按疾病划分为肝细胞癌、乙肝、丙肝、酒精性肝病、急性肝衰竭和威尔逊氏病等。其协会官方期刊《Journal of Hepatology》为月刊。, copyright=0, guiderPublishedTime=Sat Feb 06 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年2月，欧洲肝脏研究学会(EASL)发布了慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗的意见书。本文主要总结了疫苗的安全性、免疫源性以及在上述患者群体中的疗效数据，并针对这些患者接种COVID-19疫苗提供指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=103666, tagName=COVID-19疫苗)], categoryList=[CategoryDto(categoryId=35, categoryName=预防与公卫, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=103666, guiderKeyword=COVID-19疫苗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2301, appHits=42, showAppHits=0, pcHits=440, showPcHits=2259, likes=1, shares=1, comments=5, approvalStatus=1, publishedTime=Mon Mar 08 01:49:10 CST 2021, publishedTimeString=2021-02-06, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 08 01:34:57 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 14:00:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EASL意见书：慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗.pdf)])

2021 EASL意见书：慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗.pdf

下载请点击：

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=947489, encodeId=5e5394e48927, content=优秀, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb0d5320345, createdName=148a8a94m50暂无昵称, createdTime=Thu Mar 11 21:50:19 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946724, encodeId=76db946e2426, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:56:54 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946718, encodeId=6c61946e18bb, content=厉害，牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:54:55 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946512, encodeId=392094651292, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:19:37 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
2021-03-11 148a8a94m50暂无昵称

优秀

82 0
[GetPortalCommentsPageByObjectIdResponse(id=947489, encodeId=5e5394e48927, content=优秀, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb0d5320345, createdName=148a8a94m50暂无昵称, createdTime=Thu Mar 11 21:50:19 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946724, encodeId=76db946e2426, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:56:54 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946718, encodeId=6c61946e18bb, content=厉害，牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:54:55 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946512, encodeId=392094651292, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:19:37 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
2021-03-09 a6806376

厉害

88 0
[GetPortalCommentsPageByObjectIdResponse(id=947489, encodeId=5e5394e48927, content=优秀, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb0d5320345, createdName=148a8a94m50暂无昵称, createdTime=Thu Mar 11 21:50:19 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946724, encodeId=76db946e2426, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:56:54 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946718, encodeId=6c61946e18bb, content=厉害，牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:54:55 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946512, encodeId=392094651292, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:19:37 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
2021-03-09 a6806376

厉害，牛

84 0
[GetPortalCommentsPageByObjectIdResponse(id=947489, encodeId=5e5394e48927, content=优秀, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb0d5320345, createdName=148a8a94m50暂无昵称, createdTime=Thu Mar 11 21:50:19 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946724, encodeId=76db946e2426, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:56:54 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946718, encodeId=6c61946e18bb, content=厉害，牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b8f1961917, createdName=a6806376, createdTime=Tue Mar 09 10:54:55 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946512, encodeId=392094651292, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:19:37 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
2021-03-08 ms4000001441347419

赞

0 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

预防与公卫指南

2021 EASL意见书：慢性肝病，胆囊癌以及肝移植受者接种COVID-19疫苗

相关指南

拓展阅读

科室

工具

服务